Professor Jason Parsons, Cancer and Genomic Sciences, School of Medical Sciences, University of Birmingham said:
“The new funding is a fantastic recognition of our innovative research in this area. Our unique facilities put us at the forefront of radiation research and our interdisciplinary approach across the University, including collaborations with leading physics and clinical teams plus support with other colleagues across the UK, is giving us access to the very best knowledge and resources to push boundaries in radiation research.
“The funding will allow us to build capacity and really capitalise on the facilities and expertise we have here in Birmingham.”
RadNet Birmingham will include clinical colleagues with expertise in head and neck cancer, brain cancer and paediatric oncology, all cancer types that are very reliant on radiotherapy. University of Birmingham has a strong research portfolio in each of these areas which will complement the work of the Team. They are also cancers where an urgent need has been recognised. For example, glioblastoma which is the most common form of brain cancer in adults, treatments have not changed in decades so any advances will be very welcome. Similarly, paediatric oncologists are calling for kinder treatments for children with cancer, so exploring options that are targeted with fewer side effects is vital.
The RadNet Centre in Birmingham launches this month, joining existing CRUK-funded centres that have been running since 2019. Together the centres create a portfolio of internationally leading research in radiation biology and radiation oncology. Each Centre will individually focus on separate aspects such as understanding of the underpinning biological mechanisms, as well as how best to apply and deliver radiotherapy, and are intended to work collaboratively throughout the funding period.
Dr Iain Foulkes, Executive Director of Research and Innovation at Cancer Research UK said:
“Cancer Research UK, and its predecessors, have been at the forefront of radiation research for the past 120 years. Thanks to research, radiotherapy treatment is becoming kinder, more precise and less intensive across different cancers.
“This funding marks a new phase of our RadNet network, advancing research which will further accelerate improvements in radiotherapy treatment in the clinic. This funding will work alongside our investments in pioneering radiotherapy clinical trials to ensure more people can live longer, better lives, free from the fear of cancer.”
